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ABSTRACT
Changes within interstitial stromal compartments often accompany 
carcinogenesis, and this is true of prostate cancer. Typically, the tissue becomes 
populated by myofibroblasts that can promote progression. Not all myofibroblasts 
exhibit the same negative influence, however, and identifying the aggressive 
form of myofibroblast may provide useful information at diagnosis. A means of 
molecularly defining such myofibroblasts is unknown. We compared protein profiles 
of normal and diseased stroma isolated from prostate cancer patients to identify 
discriminating hallmarks of disease-associated stroma. We included the stimulation 
of normal stromal cells with known myofibroblast inducers namely soluble TGFβ and 
exosome-associated-TGFβ and compared the function and protein profiles arising. 
In all 6-patients examined, diseased stroma exhibited a pro-angiogenic influence 
on endothelial cells, generating large multicellular vessel-like structures. Identical 
structures were apparent following stimulation of normal stroma with exosomes 
(5/6 patients), but TGFβ-stimulation generated a non-angiogenic stroma. Proteomics 
highlighted disease-related cytoskeleton alterations such as elevated Transgelin 
(TAGLN). Many of these were also changed following TGFβ or exosome stimulation 
and did not well discriminate the nature of the stimulus. Soluble TGFβ, however 
triggered differential expression of proteins related to mitochondrial function 
including voltage dependent ion channels VDAC1 and 2, and this was not found in 
the other stromal types studied. Surprisingly, Aldehyde Dehydrogenase (ALDH1A1), 
a stem-cell associated protein was detected in normal stromal cells and found to 
decrease in disease. In summary, we have discovered a set of proteins that contribute 
to defining disease-associated myofibroblasts, and emphasise the similarity between 
exosome-generated myofibroblasts and those naturally arising in situ.
INTRODUCTION
Mounting clinical data emphasize the importance of 
altered stroma as a driver of cancer progression [1–3]. The 
normal homeostatic function of interstitial tissue becomes 
disturbed during the early stages of carcinogenesis [4]. 
This is accompanied by an expanding population of alpha 
smooth muscle actin (αSMA) positive myofibroblastic 
cells within the stroma. These myofibroblasts alter the 
tissue architecture, impacting organ function, and can 
aid cancer cell proliferation and survival, and support 
angiogenesis. Ultimately driving the development of high 
grade tumours associated with poor treatment response [3, 
5–7] and poor outcome [4, 8–9].
In xenotransplantation models, myofibroblastic 
stromal cells taken from cancerous [10], fibrotic or wound-
healing tissues [11] can support tumour growth in vivo, in 
part due to enhanced angiogenesis [10]. The capacity of 
stromal cells to do this, however, is variable [12] and we 
do not yet understand the nuances of the myofibroblast 
phenotype which are critical for tumour-promoting effects. 
Whilst in general terms alterations to cancer associated 
Oncotarget20125www.impactjournals.com/oncotarget
stroma may indicate poor prognoses [1–3, 13] there are 
some recent examples in pancreatic cancers where stroma 
might be protective and inhibit tumour progression [14–
15]. This demonstrates functional diversity in the nature 
of cancer reactive stroma which currently remains poorly 
understood at a molecular level. Identifying markers 
of aberrant disease promoting stroma, distinguishing 
aggressive from more indolent disease, may provide 
additional information that is useful at diagnosis [16].
The mechanisms initiating myofibroblastic 
accumulation within the tumour microenvironment centre 
on complex paracrine factors secreted by tumour cells. 
These include SDF-1 and TGFβ1 and several others, 
which may act to recruit cells from other sites into the 
cancerous tissue, such as bone marrow or adipose tissue 
derived mesenchymal stem cells [17–18]. Alternatively 
epithelial or endothelial cells in situ may differentiate 
to a mesenchymal phenotype [19]. Differentiation of 
resident fibroblasts to myofibroblasts is probably the most 
extensively studied to date [20] and argued by many to be 
the likeliest principal source of myofibroblasts. TGFβ can 
mediate differentiation of fibroblasts into myofibroblasts 
but this process in vivo takes place amongst a host of other 
factors influencing this process [20]. The manner by which 
cancer cells dictate the particular type of myofibroblast 
that arise remains a topic of great interest.
Nanometre sized vesicles, called exosomes, have 
been proposed as a mechanism by which cancer cells 
exert control over the cancer microenvironment [21]. 
This includes induction of myofibroblast differentiation 
from fibroblasts [22] or from mesenchymal stem cells of 
bone [23], umbilical cord [24] or adipose-tissue origins 
[25]. This occurs through vesicular delivery of TGFβ, and 
likely other factors, that drive stromal precursors towards 
an apparent disease-promoting myofibroblast [26]. Exactly 
how representative the stromal response to exosomes is, 
compared to stromal cells naturally educated in vivo by 
tumour cells, remains unknown.
Our presented study examines the protein repertoire 
of different forms of stromal cells using a proteomics 
approach and hypothesises that exosome-stimulation leads 
to a phenotype with shared features of in vivo educated 
myofibroblasts.
RESULTS
Stroma obtained from prostate cancer tissue 
contains myofibroblasts
We obtained biopsy material from a total of 6 
patients (from the Wales Cancer Bank), in which there 
was cancer in one half of the prostate and not the other. 
Histological examination, stained with H&E, of a 
typical pair of biopsies is shown (Figure 1A), revealing 
clear differences between the normal and disease 
tissue. Normal tissue (Figure 1A, left, showing patient 
WCB1161) demonstrated open glandular structures and a 
predominantly smooth muscle stromal architecture. This 
contrasts with disease tissue (Figure 1A, right) in which 
there was clear hypercellularity and disorganisation of 
glands, together with an altered, fibrosis-like interstitial 
stroma and infiltrate. Patient-matched biopsy-pairs 
were enzymatically homogenised and stromal cultures 
established as described in the methods.
The phenotype of the cultured cells arising was 
examined by immuno-fluorescence for a panel of 
antibodies to discriminate fibroblasts, smooth muscle cells, 
myofibroblasts and epithelial cells (Figure 1B, showing 
patient WCB1161). Cells outgrowing from normal tissue 
exhibited elongated rather than cobblestone morphology, 
and had the typical appearance of fibroblastic cells. These 
cells stained strongly positive for the mesenchymal marker 
Vimentin, but lacked the smooth muscle marker Desmin 
or the epithelial Cytokeratins. The smooth muscle and 
myofibroblast marker alpha-smooth muscle actin (αSMA) 
was absent from normal-tissue derived cultures across all 
patients. Overall the phenotype here was consistent with a 
fibroblastic cell type. When compared to morphologically 
similar cell outgrowths from matched disease tissue, 
there was no evidence of epithelial or smooth muscle 
cell (Cytokeratin and Desmin negative) outgrowth. The 
disease associated cells exhibited a Vimentin and αSMA 
double positive phenotype; consistent with myofibroblasts. 
The proportion of αSMA-positive cells in these cultures 
was variable across the 6 patients and estimations 
based on manual counting ranged from 35% to 63%. 
These therefore represent a mixture of fibroblasts and 
myofibroblasts. The raw data for the remaining 5 patients 
is shown in supplemental Fig S1 and entirely summarised 
in Table 1.
Normal stroma becomes myofibroblastic 
following stimulation by sTGFβ or cancer 
exosomes
We next examined the capacity of normal stroma to 
differentiate into myofibroblasts in response to the classical 
stimulus of sTGFβ or by treating with exosomes isolated 
from prostate cancer (Du145) cells. We previously showed 
exosomes from this source exhibits TGFβ1 tethered to the 
membrane, at a dose of ~7.5 pg TGFβ per μg of exosomes. 
In these experiments therefore a dose of 1.5ng/ml sTGFβ 
was used to trigger differentiation and this was compared 
to the equivalent dose of exosomal-TGFβ (200 μ g/ml of 
exosomes) as described [22]. The emergence of αSMA-
positivity was assessed microscopically after three days.
There was a clear cut elevation in the proportion of 
αSMA positive cells in response to sTGFβ as expected, 
although this was relatively weak for patient WCB955. 
Elevation of αSMA was present as classical stress fibres 
along the longitudinal axis of the cell body; typical of a 
contractile myofibroblastic cell phenotype (Figure 2). 
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A similar response was evident following stimulation 
with exosomes, and it was not possible to distinguish the 
stimuli used, based solely on αSMA-expression. Normal 
prostate stromal cells therefore respond equally well to 
these stimuli giving rise to a heterogeneous population of 
fibroblasts and myofibroblasts that are morphologically 
similar to those naturally occurring in diseased tissue 
(Figure 2).
Myofibroblasts exhibit differing capacity for 
driving angiogenesis
On the basis of αSMA staining alone, it was not 
possible to discriminate diseased stroma from normal 
stromal cells that had undergone differentiation in 
response to our chosen stimuli. We therefore decided to 
explore the angiogenic potential of the different stromal 
Figure 1: Characterising cultured normal or diseased stromal cells. Prostatectomy cores were paraffin embedded, sectioned and 
stained (H&E) and the histology of tissue from the non-cancerous side of the prostate (Normal Stroma) vs. the cancerous lesion (Disease 
Stroma) was compared. This is representative of 6 such tissue pairs (Scale Bar=100μm) A. Parallel cores were homogenised and used to 
establish stromal cell cultures. At passage 3 to 5, cells were seeded onto cover slip chamber slides, fixed and indirect immuno-staining was 
performed for the specified cytoskeleton proteins (Vimentin, Cytokeratin 5 and 8, Desmin or αSMA-green) and DAPI. (Scale Bar=100μm) 
B. Patient WCB1161 is shown and is representative of cultures from 6 patients. The remaining 5 patients are shown in supplemental Fig S1, 
and the phenotype for 6 patients is summarised in Table 1.
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cell types as previous studies indicate this function may 
be different across stromal cell types [9, 26].
Stromal cells were treated as above, and endothelial 
cells were added in a scattered/random fashion, to 
the stromal monolayer. After 6 days, the potential for 
endothelial cells to proliferate, migrate and organise 
into vessel-like structures was examined by staining for 
the endothelial marker CD31. The resultant structures 
can be large, so multiple 20x images were taken for 
each condition, and the tiled images were stitched. Each 
composite image therefore represents approximately ¼ of 
a 24 well plate well (Figure 3A). Untreated normal stroma 
did not support the formation of CD31-positive structures, 
other than the occasional small cell cluster, comprising 
fewer than 15 cells. In contrast, untreated disease stroma 
was potent at supporting more elaborate clusters of tens to 
hundreds of endothelial cells, forming thick and elongated 
vessel-like structures (Figure 3A). Measuring the area 
occupied by the CD31-positive structures allowed for a 
straightforward means of quantifying this pro-angiogenic 
behaviour. A representation of the typical CD31-positive 
area measured in shown in Figure 3B. This revealed a 
significant increase in CD31-positive surface area in 
response to disease stroma compared to normal stroma in 6 
of 6 patients (p<0.001, Figure 3C). Pre-stimulating normal 
stroma with sTGFβ however gave a poor angiogenic 
response, with isolated endothelial cell clusters that were 
small, and not significantly different from normal stroma 
in 5 of 6 patients (p>0.05). The angiogenic response to 
exosome-activated normal stroma was very similar to the 
disease stroma (Figure 3A), where endothelial clusters 
were large enough to merge, giving a significant elevation 
in CD31-positive area in 5 of 6 patients (Figure 3C).
From these data, the disease stromal cells and 
exosome-activated normal stromal cells exhibit similar 
pro-angiogenic behaviours in these assays. Clearly whilst 
generating genuine myofibroblasts, sTGFβ treatment 
appears not to promote a robust angiogenic response, 
representing a distinct type of myofibroblast.
Differential protein expression across 
the stromal cell types
We next examined the protein profile of these 
stromal cell types, aiming to identify elements that were 
differentially expressed. We utilised a well established 
LC-MS proteomics workflow with iTRAQ labelling as 
we previously described [27–28]. This method provides 
relative quantity information, and we have used this as a 
tool to identify proteins of potential interest.
The stromal cells were subjected to whole cell lysis 
and solubilised proteins were put through a workflow 
involving trypsin digestion, labelling with isobaric tags 
and separation by 2D-liquid chromatography. Each 
specimen was examined freshly and remaining material 
frozen for the subsequent duplicate run. Comparisons 
between fresh vs frozen revealed approximately 70% 
agreement in the identifications (data not shown) and the 
data for these technical duplicates were merged in the 
final analysis. The optimal protein loading was assessed 
using lysates containing 1, 2, 4, 8 or 10 μg, as we have 
previously observed with other cell types that less protein 
can give a greater number of protein identifications. This 
was performed using patient WCB949, and whilst this 
dose escalation generated some unique proteins, overall 
there was no real improvement in the numbers of proteins 
identified. Nevertheless, as these identifications were of 
robust quality, we have also included these in the analyses 
(annotated WCB949v accordingly) (in Figure 4 and 
supplemental Table 1). For remaining samples, these were 
applied at 10 μg into the workflow.
Differentially expressed proteins were identified 
by mass-spectrometric analysis, and relative quantity 
expressed as ratio measurements of treatments compared 
to untreated normal stroma. The volcano plots (Figure 4) 
summarise the merged data for all patients (n=6), where 
coloured symbols represent individual patients, and 
the plots depict the relative expression data (log ratio), 
against the significance (log p value). The threshold 
Table 1: Phenotyping stream cells cultured from paired biopsy tissue
Patient
Normal Disease
Gleason Vimentin Cytokeratin Desmin αSMA Vimentin Cytokeratin Desmin αSMA
WCB949 3+4 100% <1% 0% 0% 100% 0% 0% 38%
WCB955 3+4 100% 0% 0% 0% 100% 0% 0% 35%
WCB1161 4+4 100% 0% 0% 0% 100% 0% 0% 63%
WCB1358 3+4 100% 0% 0% 0% 100% 0% 0% 46%
WCB1616 3+4 100% 0% 0% 0% 100% 0% 0% 56%
WCB1628 3+4 100% 0% 0% 0% 100% <1% 0% 61%
Table summarises the pathological assessment of patients biopsy tissue for all 6 patients used in the study, and the immuno-
phenotyping analysis of stromal cells isolated from these. The numbers (%) represent an estimation of the proportion of 
positive cells. Counts were determined manually, from 3 microscopic fields.
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taken for an identification of interest was based on a fold 
change of ±1.5 and a p-value <0.01. When comparing 
disease vs normal stroma we saw the greatest number of 
differentially regulated proteins. This included 43 that 
were elevated, such as Calmodulin (CALM), Caldesmon 
(CALD1), Transgelins 1 and 2 (TAGLN), CD44, 
Calumenin (CALU) and several others. There were another 
30 identifications that were downregulated in disease, 
including Caveolin-1 (CAV1), Galectin-1 (LGALS1), 
Tropomyosin alpha-4 (TPM-4), Brain acid soluble protein 
1(BASP1) and others. The proteomics data generated 
fewer differentially expressed proteins when comparing 
exosome-stimulated normal stroma to untreated normal 
stroma (Figure 4B). Here, 8 proteins were elevated, 
including TAGLN, Calponin-1 (CNN1) and Annexin A5 
(ANXA5) and 21 were found decreased including CAV1, 
BASP1, and heat shock cognate protein 1A/1B (HSP71) 
(supplemental Table 1). Stimulations with sTGFβ (Figure 
4C) revealed a similar signature overall, with 28 elevated 
proteins including CALD1, TAGLN, FN1 and Tenascin 
(TENA). There were 13 downregulated proteins including 
again BASP1, and Tropomyosin alpha-4 (TPM-4). The 
agreement in differentially expressed proteins across 
the 6 patients ranged from 0%-26% summarised in 
supplemental Fig S2.
Using a simple Venn diagram (Figure 4D) we 
compared the identifications arising across treatment 
groups. Here we saw a set of 8 proteins that were 
differentially regulated in all conditions. There was 
an additional 8 proteins that were unique to the TGFβ-
stimulation, but only 4 identifications unique to the 
exosome-treatment. A total of 33 proteins were distinctive 
in disease stroma and these data are summarised in 
Table 2.
Confirmation of differential protein expression 
by alternative methods
From the lists of differentially expressed proteins 
we selected targets that were identified in more than one 
patient, with the expectation that these would be verifiable 
proteins. We performed a series of western blotting and 
TaqMan™ qPCR-assays to examine differences in 
expression levels across the four stromal cell types. This 
was done for all six patients and the results summarised in 
Figure 5A (protein) and 5B (mRNA), where the individual 
patients demonstrating either an increase or decrease in 
expression are shown. For western blots, this was based 
on band-densitometry and a difference in relative density 
of >1.25± fold (vs normal stroma) was considered as 
differentially expressed. The full panel of blots is shown 
in supplemental Fig S3. Similarly for the TaqMan™-
PCR data, target mRNAs were considered differentially 
expressed if fold change was >±1.25 (vs normal stroma), 
and of these, all were significantly different (p<0.05). 
The full panel of relative-expression data is shown in 
supplemental Fig S4.
With respect to protein, a band for cellular FN1 was 
found in all groups regardless of treatment, however in 
general there was a clear cut elevation in band intensity 
following short term exposure to sTGFβ or exosomes. 
This was particularly pronounced for the sTGFβ-treatment 
in all patients, whereas exosome-stimulus led to a clear 
elevation in FN1 in 4/6 patients. Band intensity for FN1 
was more variable for disease stroma, and was only 
convincing elevated in 1/6 patients, and was decreased 
in 1/6 patients. Changes therefore in FN1 were not a 
consistent feature of disease stroma, but was certainly a 
marker of recent sTGFβ or exosome-mediated stromal 
Figure 2: Stimulating normal prostate stromal cells generates myofibroblasts. Normal stromal cells were seeded onto glass-
chamber slides and growth arrested. After 3 days, media was replaced. For some wells sTGFβ (1.5ng/ml) or Du145 exosomes (200μg/ml) 
was added and after a further 3 days, the cells were fixed, and stained for αSMA (green) and DAPI. This was performed on normal stroma 
from all 6 patients as indicated.
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Figure 3: Stromal cells show differential angiogenesis supporting function. Monolayers of stromal cells were seeded into 24 
well glass-bottomed imaging plates, and were pre-treated as specified, for three days to allow differentiation to myofibroblasts. Endothelial 
cells (2x104 cell/well in 500μl) were added in a drop-wise and scattered fashion to each well. After 4 days, the cells were fixed and stained 
for CD31 and DAPI. A series of images was taken in a 4 x 3 grid using a 20x objective, for each duplicate treatment. One composite image 
is shown for each treatment for the WCB949 patient as a representative example (Scale bar=500μm) A. For each image composite, the 
surface area occupied by each CD31-positive structure was measured. Representative examples of areas taken for such measurements are 
shown B. The CD31-positive area is shown for all treatments in all 6 patients C. (*p<0.05, **p<0.01, ***p<0.001, Kruskal-Wallis test with 
Dunn’s multiple comparison post test).
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Figure 4: Proteomics analysis of stromal cell types. Volcano plots summarising the analysis of differentially expressed proteins, 
comparing Normal vs Disease stroma A. normal vs exosome-stimulated normal stroma B. normal vs sTGFβ-stimulated normal stroma 
C., where coloured symbols represent individual patients (n=6) and WCB949v- depicts the inclusion of data where the protein dose through 
the workflow was 1, 2, 4 and 8 μg instead of 10ug for all other samples. The thresholds shown indicate a p value <0.01 and a fold change 
of ±1.5. Identifications outside these criteria were not considered as differentially expressed. A Venn diagram D. shows a comparison of the 
differentially expressed protein lists, and the specific identifications are highlighted in Table 2.
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activation (Figure 5A and Fig S3). To some extent 
a similar pattern was also apparent for TPM2 where 
heightened levels were mainly seen in TGFβ1 or exosome 
stimulated cells (4/6 or 3/6 patients respectively). The 
pattern of disease related TPM2 changes was inconsistent 
with 2/6 patients demonstrating an elevation whilst 
1/6 demonstrated decreased expression (Figure 5A and 
Fig S3). Proteins such as TAGLN showed reasonable 
agreement with the MS data, and elevation was detectable 
in all 6 TGFβ1 stimulated samples, and a general trend 
towards elevation in the other samples was apparent.
Proteins such as CALU, CALD1 or BASP1 also 
showed some contradicting information in western blots, 
in terms of direction of change across the patients and 
due to this lack of consistency it was not possible to make 
any firm conclusions about these targets. Similarly NPM1 
showed hints at elevated expression, but this was seen in 
only 5 out of a possible 18 samples compared to normal 
stroma, and is unlikely to be a uniformly altered protein 
in prostate cancer stroma. Although there were some 
inconsistencies for ALDH1A1 the majority of occasions 
pointed to a decrease in this protein, and particularly so in 
disease stroma (5/6 patients).
Analysis of relative mRNA levels gave an overall 
good agreement with the western blot data. FN1 was 
elevated following treatment with sTGFβ1 or exosomes 
in 6/6 and 4/6 samples respectively, but FN1 mRNA 
expression, however, was not elevated in disease stroma 
(Figure 5B and Fig S4). There was increased mRNA 
expression of both TPM2 and TAGLN in both treated-
normal (4/6 patients each) and disease stroma (2/6 patients 
each), demonstrating good agreement with the western blot 
data. The pattern of TAGLN2, NPM1 and BASP1 mRNA 
was again inconsistent, making firm conclusions here 
difficult. However, also in agreement with the western blot 
data, ALDH1A1 mRNA expression decreased following 
Table 2: Differentially expressed proteins common and unique according to treatment
8 Proteins common 
to all treatments
8 Proteins unique 
to TGFβ-treated 
stroma
4 Proteins unique 
to Exosome-treated 
stroma
33 Proteins unique to disease stroma
TAGLN HSPB1 MAP1A CALM1 LGALS1 RPS16 AHNAK
BASP1 DES FLNC S100A6 CTTN SERPINH1 ENO1
FN1 TNC HSPA1A STMN1 COX6C MSN GSN
MYL6 VDAC1 H2AFJ EEF1B2 LASP1 ALDOA LMO7
CALU VDAC2  MARCKS YWHAZ STOM AKAP12
TPM4 SLC25A3  CNP MAP4 MYH9 TUBA1A
TGM2 ATP5B  CFL1 CD44 FLNA VIM
ALDH1A1 SOD2  NPM1 ANXA1 G6PD HBA1
   MYH10    
Table specifies the identifications according to the Venn diagram (Figure 4D), emphasising proteins which may discriminate 
the different types of stroma analysed.
TAGLN, Transgelin. BASP1, Brain acid soluble protein 1. FN1, Fibronectin, MYL6, Myosin light polypeptide 6. CALU, 
Calumenin. TPM4, Tropomyosin alpha-4 chain. ALDH1A1, aldehyde dehydrogenase 1 family member A1. HSPB1, 
Heat shock protein beta-1. DES, Desmin. TNC, Tenascin-C. VDAC1, Voltage-dependent anion-selective channel protein 
1. VDAC2, Voltage-dependent anion-selective channel protein 2. SLC25A3, Phosphate carrier protein, mitochondrial. 
ATP5B, ATP synthase subunit beta, mitochondrial. SOD2, Superoxide dismutase [Mn], mitochondrial. MAP1A, 
Microtubule-associated protein 1A. FLNC, Filamin-C. HSPA1A, Heat shock 70 kDa protein 1A/1B. H2AFJ, Histone 
H2A.J. CALM1, Calmodulin. S100A6, Protein S100-A6. STMN1, Stathmin. EEF1B2, Elongation factor 1-beta. MARCKS, 
Myristoylated alanine-rich C-kinase substrate. CNP, 2ʹ, 3ʹ-cyclic-nucleotide 3ʹ-phosphodiesterase, CFL1, Cofilin-1. NPM1, 
Nucleophosmin. MYH10, Myosin-10. LGALS1, Galectin-1. CTTN, Src substrate cortactin. COX6C, Cytochrome c oxidase 
subunit 6C. LASP1, LIM and SH3 domain protein 1. YWHAZ, 14-3-3 protein zeta/delta. MAP4, Microtubule-associated 
protein 4. CD44, CD44 antigen. ANXA1, Annexin A1. RPS16, 40S ribosomal protein S16. SERPINH1, Serpin H1. MSN, 
Moesin. ALDOA, Fructose-bisphosphate aldolase A. STOM, Erythrocyte band 7 integral membrane protein. MYH9, 
Myosin-9. FLNA, Filamin-A. G6PD, Glucose-6-phosphate 1-dehydrogenase. AHNAK, Neuroblast differentiation-associated 
protein AHNAK. ENO1, Alpha-enolase. GSN, Gelsolin. LMO7, LIM domain only protein 7. AKAP12, A-kinase anchor 
protein 12. TUBA1A, Tubulin alpha-1A chain. VIM, Vimentin. HBA1, Hemoglobin subunit alpha.
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Figure 5: Relative changes in protein and mRNA levels across the treatment groups. Western blotting was performed for 
specified target proteins, and a summary of densitometry analysis is presented. Relative band densities were compared to those of normal 
stroma, and those showing a fold change of >+1.25 were considered differentially expressed. Changes are shown for individual patients 
(each represented by coloured boxes), depicting the frequency of positive or negative change A. Similarly presented data based on the 
results of PCR-assays, depicting positive or negative changes in relative mRNA-levels for the same targets B. The raw data is shown in 
supplemental figures S3 and S4 respectively.
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treatment, either with exosomes (4/6 patients) or TGFβ1 
(5/6 patients). A reduction in aldehyde dehydrogenase 1 
family member A1 (ALDH1A1) mRNA was also a feature 
of diseased stroma in 3/6 patients (Figure 5B and Fig S4).
In conclusion, both the western blot and qPCR data 
highlight the patient-dependent variation for many of the 
selected targets, and it is therefore difficult to ascertain 
a firm profile discriminating disease stroma from the 
stimulations we have used. Overall, however proteins such 
as TPM2, TAGLN are elevated in diseased stroma, whereas 
ALDH1A1 is down regulated allowing potential for normal 
and diseased stroma to be discriminated.
DISCUSSION
The onset of myofibroblastic stroma is a general 
characteristic of tumour-influence, and is in some ways 
similar to a non-resolving wound-healing response 
long since described by Dvorak et al [29]. In some 
settings, such stromal cells support vascularisation and 
accelerate tumour growth [9–10] and promote invasion 
and ultimately metastasis through remodelling of the 
tissue architecture [30]. In contrast recent data in other 
settings, particularly perhaps in pancreatic cancers, show 
stromal cells can sometimes exert a protective, tumour 
attenuating influence [14–15]. Defining molecular features 
which can predict the functional nature of stromal cells, 
discriminating those which can promote disease from 
those which protect, is potentially useful and may provide 
additional information during histological diagnosis about 
the aggressivity of the tissue as a whole [31] .
In this report we established primary stromal cells 
from prostatectomy tissue, and explored the proteome 
of normal and diseased stroma. In agreement with the 
literature, there was clear evidence of myofibroblastic 
differentiation occurring under the influence of tumour 
in situ, as the disease-derived cells showed the principal 
myofibroblast feature, αSMA, yet lacked the smooth 
muscle marker Desmin. Certainly the diseased stroma 
showed heterogeneity, with a mixture of fibroblasts 
and myofibroblasts of varying proportions across the 6 
patients tested. Such heterogeneity may be important 
for tumour promoting function [32] and may well reflect 
the heterogeneity of the interstitial stroma in vivo as 
reported [4]. Alternatively, the heterogeneity may be an 
aspect arising due to the culture conditions used. Such 
myofibroblasts were notably absent in all cultures derived 
from normal prostate tissue; leading us to believe this 
is not a culture-artefact and is likely representative of 
the in vivo situation. The ability of the diseased cells to 
retain this phenotype along serial passaging indicates the 
tumour-mediated changes are sustained, if not permanent 
whilst in culture.
Among the aforementioned functional properties 
ascribed to cancer-associated stroma is their positive 
influence on angiogenic vessel formation and we found 
a consistent pro-angiogenic influence with in vivo-
educated diseased stroma. Even with patients WCB949 
and WCB955, where the proportion of myofibroblasts was 
relatively low (<40%) there was a significant (p<0.001) 
positive influence on vessel formation. This behaviour was 
not a property of normal stroma. Short-term stimulation 
with sTGFβ - the principal cytokine implicated in the 
generation of myofibroblasts was a potent stimulus for 
differentiation, but these myofibroblasts remained unable 
to drive the formation of vessel-like structures in 5/6 
patients. Myofibroblasts generated by sTGFβ stimulation 
of normal stroma have also shown an inability to promote 
xenograft growth in vivo and may in fact exhibit some 
control of in vivo growth [26]. In terms of this function 
the sTGFβ may represent a protective phenotype, and 
is at odds with those cells naturally arising at the sites 
of prostate cancer. Cancer-derived exosomes deliver 
functionally active TGFβ1 to fibroblasts [22] or to other 
precursors of myofibroblasts, such as mesenchymal stem 
cells [23, 25, 33] and potentially mediate formation of 
a distinct form of myofibroblast [22, 26]. This stimulus 
consistently drove myofibroblastic differentiation of 
normal prostate stroma, which in 5/6 patients became 
potent stimulators of angiogenesis in our vessel-formation 
assay. This suggests the exosomal-trigger generates 
myofibroblasts with the functions of diseased stroma, and 
agrees with our initial premise.
We are not yet sure whether or not the dose of 
exosomes used here and in these cited studies, is truly 
representative of the natural dose of vesicles present in 
tumour interstitial fluid (or in the circulation) of prostate 
cancer patients, because accurately quantifying vesicles in 
bio-fluids remains a major challenge. Certainly in studies 
by other groups, comparable doses of exosomes have been 
used to drive differentiation [25, 33], and similar doses 
also used when adding exosomes to in vivo model systems 
[34]. It is also noteworthy that whilst exosomes from 
prostate cancer can be found in the urine and circulation of 
patients [35], we show here that tissue from the opposite, 
histologically normal, side of the prostate remains 
fibroblastic as opposed to myofibroblastic in nature. This 
suggests that the diffusion of exosomes across/within the 
prostate tissue may be somewhat limited, and exosomes do 
not attain the dose required to form a general organ-wide 
activation of fibroblasts. Instead, this functional response 
to exosomes remains a relatively localised phenomenon 
at least in the specimens of Gleason 6/7 which we have 
examined.
In terms of the proteomics identifications arising, 
disease-mediated changes included a set of proteins 
related to the control of the cytoskeleton such as 
Transgelin (TAGLN), Tropomyosin-4 (TPM4), Myosin 
light chain-6 (MYL6) and heavy chain-9 (MYH9), 
Caldesmon (CALD1), Tubulin alpha-1a (TUBA1A), 
Vimentin (VIM), A-kinase anchor protein-12 (AKAP12), 
Gelsonin (GSN), Filamin A (FLNA), Moesin (MSN), 
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Cofilin-1 (CFL1) and Cortactin (CTTN) and these would 
be consistent with cytoskeleton rearrangement, necessary 
for acquiring a contractile myofibroblastic phenotype. 
TAGLN has previously been reported to be upregulated 
in TGFβ1-induced stromal myofibroblasts, generating 
a phenotype that resembled reactive stromal cells from 
patients with prostate cancer [36]. Similarly to MYL6 and 
TPM4, in our study TAGLN was differentially regulated 
irrespective of the type of stimulus, and as such these 
proteins may be general markers of activated stroma. 
Whilst we identified CALD1 within the disease stroma 
and TGFβ1-treated normal stroma by MS, western blot 
analysis also hinted at an elevation of CALD1 following 
exosome-stimulation. Increased CALD1 expression has 
been documented as a marker of developing stroma in 
human foetal prostate xenografts, and may therefore 
feature in stroma that is dynamically changing [37]. In 
contrast, proteins like cellular fibronectin (FN1) appear 
principally to be a feature of short-term stimulations in 
our hands, and sustained elevation was not a consistent 
feature of diseased stroma. In tissue sections, however 
enhanced fibronectin expression is a general documented 
aspect of tumour associated stroma [38]. It is possible that 
a lack of continual stimulation of stroma by cancer cells 
in culture explains the normal levels of FN1 we have seen 
in the diseased stromal cells; but this is an open question 
requiring additional investigations.
Other proteins seen altered in all stromal types, 
compared to normal stroma included Brain acidic soluble 
protein-1 (BASP1) and the Aldehyde dehydrogenase 
(ALDH1A1). BASP1 is a membrane and cytoskeleton-
associated protein predominantly expressed in the neurons 
of developing brains, and is functionally implicated in 
neurite outgrowth and motility [39]. This likely involves 
a function in controlling actin dynamics and membrane 
structure [40] and hence may be a hitherto undescribed 
protein involved in the acquisition of myofibroblastic 
features. Interestingly there is also an inhibitory influence 
of BASP1 on the oncogene MYC implicating BASP1 
as a tumour suppressor [41]. Its role in the stromal 
compartment is not to our knowledge known, but 
potentially BASP1 modulation may impact a host of MYC-
dependent processes in the cancer microenvironment. 
However, there were discrepancies in our data, with 
western blotting poorly supporting the MS and mRNA-
data pointing to down regulated BASP1. We therefore 
suggest this protein may be of interest in future studies, 
to ascertain its relationship with cancer-activated stroma. 
Finding modulated ALDH1A1 in stroma was similarly 
unexpected. It’s broadly acknowledged as a feature of 
cancer stem-like cells, related to radioresistance [42] 
and is a marker that can predict outcome in prostate 
cancer [43–44]. Whilst the stromal compartment may 
support a niche for ALD1A1-expressing stem cells [45], 
the importance of stromal ALDH1A1 is not known. Of 
interest, the loss of ALDH1A1 was reported to occur in 
differentiating myofibroblasts of the cornea, which would 
agree with our observations here [46], and may point to 
a general trait related to myofibroblastic differentiation 
rather than a factor to discriminate bona fide diseased 
stroma. According to the MS data, CALU was also 
differentially expressed across the stromal cell types. This 
extracellular protein, which is implicated in many cellular 
processes including motility [47] is altered in the stroma 
of colorectal cancer, and might also be expected as altered 
in prostate cancer. However, in our model, the changes in 
CALU, CALD1 and NPM1 were particularly inconsistent 
across the patients and their relevance in this setting 
remains ambiguous.
The differentially regulated proteins in disease 
stroma were not particularly related to a function in 
angiogenic control except for perhaps C-type natriuretic 
peptide (CNP) which may modulate VEGF levels and 
is implicated in vessel permeability [48], and annexin-I 
(ANXA1) which has a role in regulating VEGF function 
[49]. These identifications didn’t feature however in 
the comparably pro-angiogenic exosome-generated 
myofibroblasts, and may not be essential factors for 
this functional aspect. There was no identifiable direct 
angiogenic signature in the data for these pro-angiogenic 
stromal types. This is probably due to the nature of the 
LC-MS technology which identifies abundant components 
in complex mixtures where typically low levels of growth 
factors and cytokines are simply not detected. It is 
difficult therefore to speculate on a direct link between 
these differentially regulated proteins and the observed 
angiogenic function. A separate study of the stromal 
secretome would likely be needed for this.
The sTGFβ-generated myofibroblasts uniquely 
exhibited a striking set of altered mitochondrial proteins 
including mitochondrial voltage-dependent anion channels 
(VDAC1 and VDAC2), solute carrier family 25 member 
3 (SLC25A3), superoxide dismutase-2 (SOD2) and ATP 
synthase subunit 5 (ATP5). This is in addition to altered 
Tenascin-C (TNC) a well known matrix component 
of cancer-reactive and fibrotic stroma [50] indicating 
such changes are likely valid. Some studies have linked 
TGFβ with a series of changes to the metabolic status of 
cancer associated stromal cells, through mitochondrial 
dysfunction [51], and show such metabolic reprogramming 
of stroma is requisite for tumour-promoting activity [52]. 
Such protein changes, however, did not feature in disease-
stroma, or exosome-stimulated normal stroma and it is 
tempting therefore to suggest these changes as aspects of 
TGFβ stimulation only.
One of the important proteins downregulated in both 
disease and in exosome-stimulated stroma was Caveolin-1 
(CAV1). Diminished stromal CAV1 correlates with 
increased Gleason score, and reduced relapse-free survival 
in prostate cancer [53] and therefore marks aggressive 
disease. Although principally related to endocytosis 
and other cellular processes CAV1, is also a negative 
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regulator of TGFβ1, where loss of CAV1 boosts TGFβ 
effects. CAV1 is a marker that signals cellular autophagy, 
mitophagy and glycolytic changes are underway, as its 
loss induces mitochondrial dysfunction [54]. It will be 
of interest, therefore to examine more directly, potential 
mitochondrial alterations in stromal cells arising as a 
consequence of cancer-influence over stroma in situ.
In conclusion, utilising functional assays and a 
proteomics based approach we highlight that exosome-
activated normal stromal cells become myofibroblasts 
akin to those that naturally occurring during disease; with 
elevation in a set of cytoskeleton related proteins including 
TAGLN. In contrast, we show that the myofibroblast 
phenotype generated from sTGFβ1 stimulation is distinct, 
with poor influence on angiogenesis, exhibiting a set of 
changes in multiple mitochondrial-related components. 
Finally, our study suggests loss of ALDH1A1 as a novel 
marker for disease-related alterations in the stromal 
compartment, and future studies to better understand the 
mechanistic importance of ALDH1A1 in controlling the 
disease related myofibroblast are warranted.
MATERIALS AND METHODS
Cell culture
Primary human prostatic stromal cells were 
generated from ethically obtained tissue collected by the 
Wales Cancer Bank, from informed and fully consented 
patients. Cells were isolated from radical retropubic 
prostatectomy cores, taken from sites of palpable 
disease and also from apparently normal tissue from the 
opposite side of the same prostate. Representative cores 
were stained (H&E), and confirmed by an independent 
pathologist as cancerous stroma or normal respectively. 
Homogenized tissue was collagenase I treated (200U/
ml; Lonza, Wokingham, UK) and liberated cells 
plated in stromal cell basal medium (SCBM) (Lonza), 
which selects for stromal cell types. Cultures were left 
undisturbed for 7-10 days. At first harvest, cells were 
subsequently maintained in DMEM:F12 media (Lonza). 
These cultures were confirmed free of epithelial cells 
by immuno-fluorescence staining demonstrating lack 
of cytokeratins, and used in experiments at passage 
4-6. Endothelial cells, of human umbilical chord origin, 
were purchased from Lonza, and maintained in EBM2-
media with growth factor supplements (Lonza). For the 
angiogenesis assay supplements were withdrawn 24h 
before the experiment, and remained withdrawn for the 
duration as described [26].
Exosome isolation
Du145 prostate cancer cells (from ATCC, 
Teddington, UK), were grown in CELLine bioreactor 
flasks (Integra Biosciences AG; Hudson, NH, USA) [55] 
and used as a source of well characterised exosomes for 
this study [56]. Exosomes were purified from 7-day cell 
conditioned media using the sucrose cushion method 
[57] and, as an assessment of purity, all preparations 
had a particle to protein ratio of >2 × 1010 determined 
by nanoparticle tracking analysis (Nanosight; Malvern 
Instruments, Worcestershire, UK) and microBCA protein 
assay (ThermoFisher Scientific, Leicestershire, UK) as 
described [58].
Stimulating stromal cells
Stromal cells (normal or diseased) were grown until 
~80% confluent in 10%FBS/DMEM:F12, at which point 
they were washed three times in DMEM:F12 only, and 
allowed to growth arrest (under serum starvation) for 72 h. 
The medium was replaced for normal and diseased stroma. 
In addition, sTGFβ (1.5ng/ml) or Du145-exosomes 
(at a matched TGFβ-dose of 1.5ng/ml-TGF=200ug/
ml exosomes) was used to stimulate normal stroma. 
The titration of exosomes to determine this dose was 
previously performed as described [22-23, 26]. After 72 h, 
where peak expression of αSMA was previously observed 
[22] cellular protein (or mRNA) was assessed.
Vessel formation assay
Stromal cells seeded to 80% confluency in 24 well 
plates were growth arrested for 3 days then medium 
replaced with specified stimulus. After a further 3 days, 
endothelial cells (2 × 104/well) were added in a drop-wise 
and scattered fashion to randomly distribute them. Cells 
were left undisturbed for a further 6 days, before fixing for 
immunofluorescence as described below.
Immunofluorescent microscopy
Stromal cells were treated as specified then fixed 
with ice cold acetone : methanol (1:1 ratio) for 5 min. 
Following solvent evaporation in air, cells were blocked 
in 1%BSA/PBS for 1h. To evaluate presence of epithelial, 
smooth muscle cell and fibroblasts/myofibroblasts we 
used monoclonal antibodies against αSMA, Vimentin, 
Cytokeratins 8 and 14, and Desmin (Santa Cruz, Dallas, 
TX, USA). Primary antibodies were used at 1μg/ml, 
diluted in 0.1% BSA/PBS. After washing, secondary goat 
anti-mouse IgG Fab’-Alexa 488 conjugate (ThermoFisher 
Scientific) diluted 1 in 200 in 0.1%BSA/PBS was added 
for 1h. DAPI (ThermoFisher Scientific) was added 
for the last 10 min of incubation. After washing, cells 
were examined by wide field fluorescence microscopy 
(Axiovert; Zeiss, Cambridge, UK). Cell counts were taken 
from 3 microscopic fields, to estimate the proportion of 
αSMA-positive myofibroblasts. For vessel formation 
assay, endothelial cell-structures were visualised by 
staining with anti-CD31(Santa Cruz), at 1μg/ml, and a 
series of 4x3 tiled images taken using a motorised xy stage, 
Oncotarget20136www.impactjournals.com/oncotarget
and a 20x objective. Tiled images were stitched to form a 
composite image (using Zen-blue edition 2012 software, 
Zeiss) and the 2D-area occupied by CD31-positive 
structures was measured using the Zen-blue software. A 
composite image was made from each duplicate well per 
condition and all CD31-positive structures in the image 
measured. Data are presented as dot-plots (individual 
measurements) with the mean, for each condition for all 
6 patients.
Preparation of peptides for nano-LC
Stromal cells were washed twice in warm PBS, 
prior to addition of lysis buffer containing 20nM TEAB, 
1% SDS (w/v), 1%NP-40 (v/v) and harvested using a 
cell scraper at room temperature. After centrifugation 
to remove insoluble material (5000g/10min), clarified 
supernatants were subjected to solvent precipitation to 
remove salts, lipids and detergent (using the 2D clean-up 
kit;GE Healthcare, Buckinghamshire, UK). The pellets 
were resuspended in 20 mM TEAB and left overnight 
at 4°C. The protein content was then determined using 
the BCA protein assay kit. Samples were then reduced, 
denatured and alkylated using an iTRAQ labelling kit 
(Applied Biosystems,) and the standard protocol. The 
proteins were subjected to digestion with trypsin, 0.8 
µg per sample, and incubated at 37°C for 12-16 h. The 
samples were then dried and resuspended in water with 
0.1 % TFA (v/v).
LC-MALDI and protein identification
Digested peptides (10μg) were separated on a nano-
LC system (UltiMate 3000, Dionex, Sunnyvale, USA) 
using a two-dimensional salt plug method, as previously 
described [27]. Mass spectrometry was performed using 
an Applied Biosystems 4800 MALDI TOF/TOF mass 
spectrometer, as described [27]. The MS/MS data was 
used to search the latest available Swiss-Prot database (as 
of 07/2013) using the MASCOT Database search engine 
v2.1.04 (Matrix Science Ltd, London, UK), embedded 
into GPS Explorer software v3.6 Build 327 (Applied 
Biosystems, ThermoFisher Scientific) (default GPS 
parameters, 1 missed cleavage allowed, fixed modification 
of MMTS(C), variable modifications of oxidation (M), 
pyro-glu (N-term E) and pyro-glu (N-term Q), 150 ppm 
mass tolerance in MS and 0.3 Da mass tolerance for MS/
MS which are recommended published tolerances for LC-
MALDI [27]. In order for a protein to be identified, there 
needed to be a minimum of two peptides with MASCOT 
e-values less than 0.05. There was a false discovery rate 
(FDR) of 0 % which was determined using the same 
SwissProt database with the entire sequence randomised. 
Where more than one protein was identified, the protein 
with the highest MOWSE score in MASCOT is reported. 
The analysis was performed with two technical replicates 
and the data was merged. This was done for a total of 
6-patients. For one of the patients, WCB949, the protein 
amount run through the LC-MALDI was escalated from 1, 
2, 5 , 8 to 10μg. The data generated here was also included 
in the analysis and annotated WCB949V (for “variable 
loading”) in figures and tables.
MS data analysis
MS-spectra were analysed using ProteinPilot™ 
(AB-Sciex, Cheshire, UK) running the Paragon™ 
algorithm [59]. The generated protein and peptide 
searches were imported into the ProteinPilot™ Descriptive 
Statistics Template (PSDT), which enabled rapid 
assessment of the quality of protein identifications and of 
relative quantity. We report the PSDT output expressing 
relative quantity estimations as ratiometric data, relative 
to the normal stroma (normalized to a value of 1). Proteins 
were considered differentially expressed if the fold 
change was ≥±1.5 and p-value < 0.01. Data are presented 
as volcano plots for each treatment condition, and the 
thresholded data presented as Supplemental Table 1.
Electrophoresis and immuno-blotting
Stromal cell lysates were generated using RIPA 
buffer supplemented with 1% protease inhibitors, 
1% phenymethylsulfonyl fluoride, and 1% sodium 
orthovanadate (Santa Cruz). Insoluble material was 
removed (5000 x g centrifugation) and protein levels 
determined by Bradford assay (BioRad, Hertfordshire, 
UK). Protein samples (10μg) were separated through 
4-12% NuPAGE™ polyacrylamide gels, with MOPS 
running buffer (ThermoFisher Scientific ). Subsequently, 
proteins were transferred to PVDF membranes (GE 
Healthcare), membranes blocked with 5% nonfat 
powdered milk and 0.1% Tween-20 in PBS for 1 h, and 
then incubated with primary monoclonal antibody at a 
concentration of 1-4μg/ml at 4°C overnight. After washes 
in 0.1% Tween-20/PBS bands were detected using an 
anti-mouse IgG-horseradish peroxidase conjugated 
antibody (Santa Cruz) and chemiluminescence substrate 
(PicoWest, ThermoFisher Scientifc). Primary antibodies 
included anti- cellular fibronectin (Enzo Life Sciences, 
Exexter, UK), Caldesmon (ThermoFisher Scientific), 
Calumenin (Santa Cruz), Tropomyosin-2 (ThermoFisher 
Scientific), Transgelin-1 (R&D Systems, Abingdon, 
UK) and Transgelin -2 (Santa Cruz), Nucleophosmin 
(ThermoFisher Scientific), Aldehyde dehydrogenase 
(ALDH1A1; R&D Systems), and brain acidic 
soluble protein-1 (BASP1; ThermoFisher Scientific). 
Densitometric analysis of western blots was performed 
using Image J software (NIH, Bethesda, ML, USA). 
Proteins were considered differentially expressed if 
relative band density was >±1.25 that observed from the 
patient-matched untreated normal stroma sample.
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Quantitative (q-PCR)
Extraction of cellular RNA, reverse transcription and 
PCR was performed as described [22]. The comparative 
CT method was used for relative quantification of target 
gene expression against that of a standard reference gene 
(GAPDH). Data were analyzed using StepOne software 
(Applied Biosystems, ThermoFisher Scientific). Target 
mRNAs were considered differentially expressed if fold 
change was >±1.25 that of the patient-matched untreated 
normal stroma sample.
Statistics
Graphs and statistical analyses were performed 
using Prism-4 software (version 4.03) from Graph Pad, 
San Diego, CA. In all experiments, with more than two 
experimental groups, 1-way ANOVA, with Tukey’s post 
test was used. For the vessel-formation assay a Kruskal-
Wallis test with Dunn’s multiple comparison post test was 
performed. Differences with p values of 0.05 or less are 
considered significant *p<0.05, **p<0.001, ***p<0.0001.
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